First report of an extensively drug-resistant VIM-2 metallo-β-lactamase-producing Brevundimonas diminuta clinical isolate
- PMID: 22692741
- PMCID: PMC3421493
- DOI: 10.1128/JCM.00924-12
First report of an extensively drug-resistant VIM-2 metallo-β-lactamase-producing Brevundimonas diminuta clinical isolate
Abstract
In the literature, only three Brevundimonas diminuta environmental isolates carrying metallo-β-lactamase genes were recently published. However, so far, no B. diminuta clinical isolates carrying these carbapenem resistance genes have been described. Here we report the first VIM-2 metallo-β-lactamase-producing B. diminuta clinical isolate obtained from an immunocompromised patient.
References
-
- Clinical and Laboratory Standards Institute 2008. Performance standards for antimicrobial susceptibility testing; M100-S18, 18th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA
-
- Han XY, Andrade RA. 2005. Brevundimonas diminuta infections and its resistance to fluoroquinolones. J. Antimicrob. Chemother. 55:853–859 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Miscellaneous
